BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, January 10, 2025
See today's BioWorld
Home
» BioCryst, Mundipharma Enter Deal Potentially Worth $190M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
BioCryst, Mundipharma Enter Deal Potentially Worth $190M
Feb. 3, 2006
By
Jennifer Boggs
No Comments
BioCryst Pharmaceuticals Inc. is expanding development and marketing for its lead product, Fodosine, through a potential $190 million oncology deal with Mundipharma International Holdings Ltd. (BioWorld Today)
BioWorld
